Antimicrobial polypeptides

Truncated HBP-5 variants address proteolytic degradation and toxicity issues, offering improved stability and efficacy against multi-drug-resistant microbes, suitable for clinical and veterinary use.

WO2026234259A1PCT designated stage Publication Date: 2026-11-12UNIVERSITAT AUTONOMA DE BARCELONA +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063475
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing antimicrobial peptides, such as HBP-5, face challenges including susceptibility to proteolytic degradation, poor stability, short half-life, and toxicity to mammalian cells, limiting their clinical and veterinary use, especially against multi-drug-resistant microbes.

Method used

Development of truncated HBP-5 variants, denoted as HBP-5[1-20], with improved proteolytic stability, longer half-life, and reduced toxicity, exhibiting enhanced antimicrobial activity against Gram-negative bacteria.

Benefits of technology

The HBP-5[1-20] variants demonstrate higher antimicrobial efficacy, longer serum half-life, and lower toxicity, making them suitable for therapeutic applications against multi-drug-resistant pathogens.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000037_0001
    Figure IMGF000037_0001
  • Figure IMGF000040_0001
    Figure IMGF000040_0001
  • Figure IMGF000040_0002
    Figure IMGF000040_0002
Patent Text Reader

Abstract

The present disclosure provides a polypeptide or a pharmaceutically acceptable salt thereof consisting of from 20 to 22 amino acid residues in length, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2 or of a variant of SEQ ID NO: 2 comprising up to 5 residue substitutions. The disclosure also provides a conjugate or a pharmaceutically acceptable salt thereof comprising the polypeptide, a pharmaceutical composition comprising the polypeptide or the conjugate, and the polypeptide for use as a medicament, particularly for use in the treatment and / prevention of a pathological condition caused by a microbe.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Antimicrobial polypeptides

[0002] This application claims the benefit of European Patent Application EP25382466.8 filed on 09.05.2025.

[0003] Technical Field

[0004] The present disclosure relates to the field of clinical and veterinary microbiology. In particular, it relates to new polypeptides and their uses as antimicrobial agents. The polypeptides of the present disclosure are particularly useful for eliminating Gram-negative bacteria.

[0005] Background Art

[0006] Microbial infections are a significant global health concern, causing a wide range of diseases that affect millions of people each year. These infections, caused by bacteria, fungi, viruses, and parasites, can lead to severe complications and are estimated to cause over 12 million deaths every year, with over 7.7 million of these events linked to infections caused by bacteria. The growing problem of multi-drug resistance (MDR), where microbial pathogens evolve to withstand the effects of multiple antibiotics, has further complicated the treatment of infections, rendering many conventional drugs ineffective.

[0007] In response to this growing crisis, antimicrobial (poly)peptides (AMPs) have gained considerable attention as a promising alternative or adjunct to traditional antibiotics. AMPs are small, typically cationic peptides that possess the ability to inhibit or kill a broad spectrum of microorganisms, including bacteria, fungi, viruses, and parasites. AMPs can offer several advantages, including broad-spectrum activity against a wide range of pathogens, rapid action, the ability to disrupt microbial membranes, lower likelihood of inducing resistance and the ability to combat resistant bacteria. These unique properties make AMPs a valuable tool in the fight against microbial pathogens,

[0008] Several classes of AMPs have been described in literature, examples of which include defensins and alphahelical peptides, or, for example, peptides derived from heparin-binding proteins (HBPs), such as HBP-5, a 23-amino acid polypeptide derived from human Heparin cofactor 2 protein (Uniprot ID: P05546). The latter, binds lipopolysaccharide (LPS) present on the bacterial wall and displays antimicrobial activity, particularly against Gram-negative bacteria.

[0009] Despite the promising potential of AMPs, several challenges limit their widespread clinical and veterinary use. One major shortcoming is their susceptibility to proteolytic degradation by proteases present in biological fluids and tissues, which can reduce their efficacy. Additionally, many AMPs face issues with poor stability, short half-life and poor bioavailability, making it difficult to achieve and / or maintain therapeutic concentrations in biological fluids or tissues. Furthermore, their membrane-disruptive mechanisms, while effective against microbial pathogens, often cause toxicity to mammalian, including human cells, thus leading to unwanted side-effects. Finally, the in vivo activity of prior art AMPs, including HBP-5, has either not been reported or is not sufficient to ensure clinical and / or veterinary utility.Thus, there remains an urgent need for efficacious antimicrobial polypeptides with improved half-life, lower toxicity to human and other mammalian cells, and which show high efficacy towards specific pathogens, particularly towards clinically relevant microbial pathogens and MDR microbial pathogens.

[0010] Summary of Invention

[0011] The present disclosure provides new, shorter polypeptide variants of HBP-5 that address the aforementioned challenges through improved antimicrobial activity, reduced toxicity, improved proteolytic stability and longer half-life in serum. Thus, the present disclosure provides polypeptides of improved utility in clinical and veterinary applications.

[0012] Surprisingly, the inventors have found that a truncated version of HBP-5 - which is denominated HBP-5[1-20] in the experimental examples provided herein - has longer half-life in serum and improved antibacterial efficacy, compared both to the original, full-length HBP-5 and to a prior art polypeptide, denominated NLF20, which represents another truncated version of HBP-5 and has an identical length to HBP-5[1-20], Importantly, as shown in the experimental assays below using both in vitro and in vivo models, the HBP-5-derived shorter polypeptides provided herein, compared to prior art polypeptides, display higher antimicrobial activity, lower toxicity and longer half-life, as well as being more stable, due to their increased resistance to degradation by proteases present in biological fluids, which makes them suitable for therapeutic applications. All of these characteristics make the polypeptides of the disclosure an important pharmacological alternative in the treatment of pathological conditions caused by microbial agents, such as bacterial infections, in particular infections caused by multi-drug-resistant (MDR) microbes. Surprisingly, the polypeptides of the present disclosure displayed higher antimicrobial activity in females compared to males.

[0013] Thus, in a first aspect, the present disclosure provides a polypeptide or a pharmaceutically acceptable salt thereof consisting of from 20 to 22 amino acid residues in length, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2 or of a variant of SEQ ID NO: 2 comprising up to 5 residue substitutions, and wherein the polypeptide has antimicrobial activity. .

[0014] A second aspect of the present disclosure provides a conjugate or a pharmaceutically acceptable salt thereof comprising the polypeptide or the pharmaceutically acceptable salt thereof according to the first aspect, and one or more conjugate moieties.

[0015] A third aspect relates to a polynucleotide encoding the polypeptide according to the first aspect.

[0016] A further, fourth aspect, provides a construct comprising the polynucleotide according to the third aspect, while a fifth aspect provides a host cell comprising the polynucleotide according to the third aspect or the construct according to the fourth aspect.

[0017] In a sixth aspect, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically effective amount of the polypeptide or the pharmaceutically acceptable salt thereofaccording to the first aspect, the conjugate or the pharmaceutically acceptable salt thereof according to the second aspect, the polynucleotide according to the third aspect, or the construct according to the fourth aspect, and at least one pharmaceutically acceptable excipient.

[0018] A seventh aspect of the present disclosure relates to a kit of parts comprising the polypeptide or the pharmaceutically acceptable salt thereof according to the first aspect, the conjugate or the pharmaceutically acceptable salt thereof according to the second aspect, the polynucleotide according to the third aspect, the construct according to the fourth aspect, the host cell according to the fifth aspect, or the pharmaceutical composition according to the sixth aspect, and instructions for its use.

[0019] An eight aspect provides the polypeptide or the pharmaceutically acceptable salt thereof according to the first aspect, the conjugate or the pharmaceutically acceptable salt thereof according to the second aspect, the polynucleotide according to the third aspect, the construct according to the fourth aspect, the host cell according to the fifth aspect, or the pharmaceutical composition according to the sixth aspect for use as a medicament.

[0020] Furthermore, a ninth aspect provides the polypeptide or the pharmaceutically acceptable salt thereof according to the first aspect, the conjugate or the pharmaceutically acceptable salt thereof according to the second aspect, the polynucleotide according to the third aspect, the construct according to the fourth aspect, the host cell according to the fifth aspect, or the pharmaceutical composition according to the sixth aspect for use in the treatment and / or prevention of a pathological condition caused by a microbe.

[0021] The ninth aspect can also be formulated as a method of treating and / or preventing a pathological condition caused by a microbe in a subject in need of thereof, the method comprising administering to the subject the polypeptide or the pharmaceutically acceptable salt thereof according to the first aspect, the conjugate or the pharmaceutically acceptable salt thereof according to the second aspect, the polynucleotide according to the third aspect, the construct according to the fourth aspect, the host cell according to the fifth aspect, or the pharmaceutical composition according to the sixth aspect.

[0022] The ninth aspect can alternatively be formulated as the use of the polypeptide or the pharmaceutically acceptable salt thereof according to the first aspect, the conjugate or the pharmaceutically acceptable salt thereof according to the second aspect, the polynucleotide according to the third aspect, the construct according to the fourth aspect, the host cell according to the fifth aspect, or the pharmaceutical composition according to the sixth aspect, for the manufacture of a medicament for the treatment and / or prevention of a pathological condition caused by a microbe.

[0023] A tenth aspect of the present disclosure provides an in vitro method for disinfecting a material and / or surface, the method comprising contacting the polypeptide or the pharmaceutically acceptable salt thereof according to the first aspect, or the conjugate or the pharmaceutically acceptable salt thereof according to the second aspect, with the material and / or surface.

[0024] The tenth aspect can also be formulated as an in vitro use of the polypeptide or the pharmaceuticallyacceptable salt thereof according to the first aspect, or of the conjugate or the pharmaceutically acceptable salt thereof according to the second aspect, for disinfecting materials and / or surfaces.

[0025] In an eleventh aspect, the present disclosure relates to a process for the production of the polypeptide as defined in the first aspect, the process comprising (i) culturing the host cell as defined in the fifth aspect; or, alternatively, (ii) in vitro transcription and / or translation of the polynucleotide according to the third aspect or the construct according to the fourth aspect.

[0026] Brief Description of Drawings

[0027] FIGs. 1A-F show HLPC profiles (top; x axis = retention time [minutes]; y axis = milli-absorbance units, mAU) and electrospray ionization mass spectrometry (ESI-MS) spectra (bottom; x axis = mass divided by charge, m / z; y axis = relative intensity) of purified polypeptides. Each pair of HPLC and ESI-MS graphs displayed in each panel show data for one polypeptide, as indicated in the upper right corner of the graphs showing the HPLC spectra.

[0028] FIG. 2A shows NMR weighted chemical shift differences (A5W= [(6HNbound- 6HNfree)2+ (5Habound- 6Hafree)2]1 / 2, ppm) induced by the presence of the heparin disaccharide H1S plotted as a function of peptide sequence. Peptide / disaccharide ratio 1:1. The horizontal line indicates the A5W= 0.05 ppm. Residues with values below this line are considered unaffected by interaction.

[0029] FIG. 2B shows the structure of the HBP-5 polypeptide bound to the heparin analog Arixtra as defined by MD simulation.

[0030] FIG. 2C shows a summary of the distances calculated between the CPC residues involved in heparin binding as observed in the MD simulation.

[0031] FIG. 3 shows the results of structure-activity relationship study of HBP-5 and CPC mutants. FIG. 3A shows LPS affinity measured as increase in fluorescence emission (Aem= 620 nm) of BODIPY-cadaverine at different polypeptide concentrations. FIG. 3B shows heparin-binding affinities in FPLC chromatography. FIGs. 3C and 3D show CD spectra of peptides in 50 pig / mL LPS and 20 pig / mL heparin, respectively.

[0032] FIG. 4A shows the proteolytic stability of HBP-5 and HBP-5[1 -20] polypeptides. Peptide extinction curves over time were obtained by integration of chromatogram peaks displayed in FIG. 5. The peptide half-life (ti / 2) was estimated by experimental data fitting to an exponential decay model. Data are shown as the mean ± SEM of the three independent experiments.

[0033] FIG. 4B shows the proteolytic stability of the NLF20 polypeptide.

[0034] FIG. 5 shows RP-HPLC chromatograms of peptides in human serum. Elution profiles after incubation of HBP-5 (A) and HBP-5[1 -20] (B) with 50% (v / v) human serum at representative times, using a 0% to 95% ACN gradient over 15 min. The peaks at tO correspond to the intact peptide.

[0035] FIG. 6 shows anti-infective activity of antimicrobial polypeptides in an animal model. FIG. 6A shows aschematic representation of the sepsis experimental mouse model used to assess AMPs (n = 6) against A. baumannii ATCC 15308. FIG. 6B shows average CFU / mg in organs after 18 h treatment. Statistical significance compared to vehicle was determined using two-way ANOVA followed by Dunnett's test (denoted as **** p < 0.0001).

[0036] Detailed description of the invention

[0037] All terms as used in this application, unless otherwise stated, shall be understood in their ordinary meaning as known in the art. Other more specific definitions for certain terms as used in the present application are as set forth below and are intended to apply uniformly through-out the specification and claims unless an otherwise expressly set out definition provides a broader definition.

[0038] As used herein, the indefinite articles "a” and "an” are synonymous with "at least one” or "one or more.” Unless indicated otherwise, definite articles used herein, such as "the” also include the plural of the noun. As explained above, the inventors propose polypeptides or pharmaceutically acceptable salts thereof derived from the HBP-5 polypeptide, itself derived from the heparin-binding protein Heparin Cofactor 2.

[0039] A "polypeptide” or "peptide” refers to a chain of amino acids linked by a peptide bond (i.e., amide bonds) including 2 or more amino acids. The terms polypeptide and peptide are used here interchangeably. As the skilled person will know, polypeptides can be produced by synthetic routes that belong to the common general knowledge, for example by solid-phase peptide synthesis on a Rink amide resin using Fmoc-o-amine-protected amino acid. They can also be produced biologically, for example, using recombinant bacteria. Variants of polypeptides may be produced using methods of protein engineering and site-directed mutagenesis well known in the art.

[0040] The novel antimicrobial polypeptides herein disclosed bind heparin and lipopolysaccharide (LPS).

[0041] The skilled person is aware that "heparin” refers to a naturally occurring, negatively-charged glycosaminoglycan (GAG) that primarily functions as an anticoagulant and which is composed of a sequence of sulphated disaccharide units, such as, but not limited to, glucosamine and uronic acid. Proteins that possess the ability to bind heparin are commonly referred to as "heparin-binding proteins”. Regions containing basic amino acids, in particular lysine and arginine, present in such proteins are thought to be important for mediating their binding to heparin.

[0042] "Lipopolysaccharide”, also known as LPS, refers to a complex macromolecule consisting of a lipid component (lipid A) and a polysaccharide component. The skilled person is aware that LPS is a major structural component of the outer membrane of Gram-negative bacteria, that it plays a key role in bacterial structural integrity and function, and that it is known to induce immune responses such as inflammation and fever in host organisms infected with Gram-negative bacteria. Without wishing to be bound by theory, binding to LPS confers to the novel polypeptides herein disclosed particularly high efficacy against Gram-negative bacteria. As used herein, the term "pharmaceutically acceptable salt”, when referred to the polypeptide of thedisclosure, refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and non-human animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, trifluoroacetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Salts derived from appropriate bases include alkaline metal, alkaline earth metal, and ammonium. Representative alkaline or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counter ions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate.

[0043] It will be appreciated by the person skilled in the art that the term "amino acid”, as used herein, includes the standard twenty genetically-encoded alpha-amino amino acids, omega-amino acids, natural beta-amino acids (e.g., beta-alanine), other naturally-occurring amino acids, unconventional amino acids (e.g., a,a-disubstituted amino acids, N-alkyl amino acids, etc), chemically derivatised amino acids, and unnatural amino acids. The term "unnatural amino acid” comprises D-enantiomers of the 19 common chiral naturally occurring alphaamino acids. Each one of the amino acids forming the peptide of the disclosure can have, independently from the others, L- or D-configuration. Amino acids used in the preparation of the peptides of the present disclosure may be prepared by organic synthesis, or obtained by other routes, such as, for example, degradation of or isolation from a natural source.

[0044] In a first aspect, the present disclosure provides polypeptide or a pharmaceutically acceptable salt thereof consisting of from 20 to 22 amino acid residues in length, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2 or of a variant of SEQ ID NO: 2 comprising up to 5 residue substitutions, and wherein the polypeptide has antimicrobial activity. The skilled person understands that the wording "consisting of from 20 to 22 consecutive amino acid residues” refers to the amino acid sequence of the polypeptide and does not exclude the presence of counterions, such as a cation or an anion, which may be present in the pharmaceutically acceptable salt of the polypeptide. Thus, in other words, the first aspect of the present disclosure provides: (i) a polypeptide consisting of from 20 to 22 consecutive amino acid residues of SEQ IDNO:2 or of a variant of SEQ ID NO: 2, wherein the variant comprises up to 5 residue substitutions, and wherein the polypeptide has antimicrobial activity, as well as (ii) a pharmaceutically acceptable salt of the polypeptide defined in (I). The skilled person understands that a "residue substitution” refers to the replacement of one amino acid residue in a polypeptide sequence with a different amino acid residue.

[0045] Therefore, a residue substitution does not alter the length of the polypeptide sequence. In other words, a residue substitution does not allow the mere removal of a residue (deletion) from or inclusion of an additional residue (addition) in a polypeptide sequence. Residue substitutions may involve conservative or nonconservative changes. The latter are typically made to alter the properties, activity, stability, or structure of the polypeptide.

[0046] In a particular embodiment, the residue substitutions are conservative residue substitutions. A "conservative residue substitution” as used herein refers to the replacement of an amino acid in a protein sequence with another amino acid that shares similar physicochemical properties, including but not limited to size, charge, polarity, and hydrophobicity. Such residue substitutions typically aim to maintain the functional and structural integrity of the protein while allowing for variation in the sequence. The skilled person, using common general knowledge, is capable of determining suitable conservative residue substitutions for each amino acid in a polypeptide.

[0047] In another particular embodiment, residue substitutions in positions 1, 3, 8, 9, 10, 13, or 14 of SEQ ID NO: 2 are conservative residue substitutions. In a more particular embodiment, the variant does not comprise residue substitutions in positions 9, 10, and 14 of SEQ ID NO: 2. In an alternative more particular embodiment, residue substitutions comprised in the variant of SEQ ID NO: 2 are residue substitutions at positions selected from positions 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, and 23 of SEQ ID NO: 2. In an even more particular embodiment, the variant does not comprise residue substitutions in positions 1, 3, 8, 9, 10, 13, and 14 of SEQ ID NO: 2. In an alternative even more particular embodiment, residue substitutions comprised in the variant of SEQ ID NO: 2 are residue substitutions at positions selected from positions 2, 4, 5, 6, 7, 11, 15, 16, 17, 18, 19, 20, 21, 22, and 23 of SEQ ID NO: 2. The skilled person understands that SEQ ID NO: 2 differs from SEQ ID NO: 1 only in that SEQ ID NO: 2 lacks the last three amino acids of SEQ ID NO: 1. In other words, that positions 1 to 20 of SEQ ID NO: 1 are identical to positions 1 to 20 of SEQ ID NO: 2.

[0048] In a further aspect, the present disclosure also provides a polypeptide or a pharmaceutically acceptable salt thereof comprising from 19 to 22 consecutive amino acid residues of SEQ ID NO: 2 or of a variant of SEQ ID NO: 2, wherein the variant has an amino acid sequence at least 75% identical to SEQ ID NO: 2, wherein the polypeptide is from 19 to 22 amino acids in length, and wherein at least one of the last three positions of the polypeptide amino acid sequence is occupied by an amino acid selected from: histidine, lysine, and arginine. In a particular embodiment, the polypeptide comprises a residue selected from histidine, lysine, and arginine in the last position. The skilled person understands that positions in a polypeptide are numbered starting from the N-terminus, with the amino acid residue present at the N-terminus of the polypeptide representing position number 1. Thus, the skilled person understands that "the last three positions” refers to the three residuesclosest to the C-terminus of the polypeptide. Similarly, the "last position” of a polypeptide is occupied by the amino acid residue occupying the C-terminal position in the polypeptide. Without wishing to be bound by theory, the identity of the amino acid residues in the last three positions of the polypeptide, particularly the identity of the amino acid residue in the last position of the polypeptide, affects its proteolytic stability in serum. Thus, the identity of the amino acids occupying the last three positions of the polypeptide amino acid sequence, particularly the identity of the amino acid occupying the last position, may advantageously enhance the polypeptide's half-life.

[0049] In the present disclosure the term "identical" or "identity" in relation to a sequence refers to the percentage of positions that are identical in the two sequences when the sequences are optimally aligned. If, in the optimal alignment, a position in a first sequence is occupied by the same nucleotide or amino acid as the corresponding position in the second sequence, the sequences exhibit identity with respect to that position. In the context of the present disclosure, a position in an alignment where an L-enantiomer is present in one sequence, but the D-enantiomer is present in the second sequence is regarded as a position with identical residues. The percentage of identity determines the number of identical nucleotides or amino acids over a defined length in a given alignment. Thus, the level of identity between two sequences or ("percent sequence identity") is measured as a ratio of the number of identical positions shared by the sequences with respect to the number of positions compared (i.e., percent sequence identity = (number of identical positions / total number of positions compared) x 100). A gap, i.e., a position in an alignment where a nucleotide or amino acid is present in one sequence but not in the other, is regarded as a position with non-identical nucleotide or amino acid and is counted as a compared position.

[0050] As an illustration, by a polypeptide having an amino acid sequence having at least, for example, 95% identity to a reference amino acid sequence is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence of at least 95% identical to a reference amino acid sequence, amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or additional amino acid residues may be inserted into the reference sequence, such that the total count of deleted, substituted and inserted residues represents no more than 5% of the number of amino acid residues in the reference sequence. Thus, to obtain a polypeptide having an amino acid sequence of at least 95% identical to the reference amino acid sequence of SEQ ID NO: 1 or to the reference amino acid sequence of SEQ ID NO: 2, one amino acid residue may be deleted, inserted or substituted in the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, respectively. These alterations of the reference sequence may occur at the amino- or carboxy-terminal positions of the reference amino acid sequence, or they may occur anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

[0051] A number of mathematical algorithms for rapidly obtaining the optimal alignment and calculating identity between two or more sequences are known in the art and incorporated into a number of available softwareprograms. For purposes of the present disclosure, the sequence identity between two nucleic acid or amino acid sequences is preferably determined using algorithms based on global alignment, such as the Needleman-Wunsch algorithm (as disclosed in Needleman and Wunsch, "A general method applicable to the search for similarities in the amino acid sequence of two proteins”, 1970, J. Mol. Biol., vol. 48, issue 2, pp. 443-453), preferably implemented in the Needle program of the EMBOSS package (as disclosed in Rice et al., "EMBOSS: The European Molecular Biology Open Software Suite”, 2000, Trends Genet., vol. 16, issue 6, pp. 276-277); or the BLAST Global Alignment tool (as disclosed in Altschul et al., "Basic local alignment search tool”, 1990, J. Mol. Biol, vol. 215, issue 3, pp. 403-410), using default settings. Local alignment also can be used when the sequences being compared are substantially the same length.

[0052] The polypeptide or the pharmaceutically acceptable salt thereof, as defined in the aspects above, has antimicrobial activity. In particular embodiments, the antimicrobial activity is antibacterial activity.

[0053] In particular embodiments, the antimicrobial activity is at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100% higher compared to the antimicrobial activity of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1. In more particular embodiments, the antimicrobial activity is at least 50% higher compared to the antimicrobial activity of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1. In other particular embodiments, the antimicrobial activity comprises a minimum inhibitory concentration (MIC) value that is at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% lower than the MIC value of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1. In other more particular embodiments, the antimicrobial activity comprises a minimum inhibitory concentration (MIC) value that is at least 25% lower than the MIC value of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0054] Antimicrobial activity may be measured through standard protocols for antimicrobial susceptibility testing (AST), such as by determining the minimum inhibitory concentration (MIC). Methods for determining the MIC of an antimicrobial agent are well known in the art, for example, as disclosed in the European Committee's for Antimicrobial Susceptibility Testing (EUCAST) discussion document "Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution”, 2003, Clinical Microbiology and Infection, vol.

[0055] 9, issue 8, pp. ix - xv, or as disclosed in Barnes et al., "Antimicrobial susceptibility testing to evaluate minimum inhibitory concentration values of clinically relevant antibiotics”, 2023, STAR Protocols, vol. 4, issue 3, pp. 102512, or as disclosed in Andrews, "Determination of minimum inhibitory concentrations”, 2001, J.

[0056] Antimicrob. Chemother., vol. 48, suppl. issue 1, pp. 5-16. Furthermore, methods for determining the MIC of the polypeptides of the present disclosure are provided in the Examples section.

[0057] The skilled person is aware that the "minimum inhibitory concentration” (MIC) of an AMP is the lowest concentration of the polypeptide that prevents the visible growth or replication of a microorganism, such as bacteria, fungi, or viruses, under defined experimental conditions. The MIC value thus serves as a measure of the antimicrobial activity of the peptide, indicating its potency in inhibiting microbial growth. The skilled personfurther understands that the MIC value is inversely proportional to the polypeptide's antimicrobial activity. In other words, the lower the MIC (i.e. the lower the concentration of a polypeptide needed to inhibit microbial growth), the higher the antimicrobial activity of the polypeptide being tested.

[0058] Similarly, a minimum bactericidal concentration (MBC) of an AMP refers to the lowest concentration of the polypeptide that, under defined in vitro conditions, reduces by 99.9%, the number of viable microorganisms in a medium. The MIC and MBC values are commonly expressed as molar concentrations, which the skilled person understands refers to the number of moles of a given polypeptide per litre of solution.

[0059] In more particular embodiments, the antibacterial activity is selective antibacterial activity towards a Gramnegative bacterium, even more particularly towards a bacterium of the genus Pseudomonas, most particularly towards a Pseudomonas aeruginosa bacterium. In further particular embodiments, the antibacterial activity is bacteriostatic activity, bactericidal activity, or a combination thereof. In this sense, "bacteriostatic activity” refers to the ability to inhibit the growth or reproduction of bacterial cells, without causing their immediate death. Bacteriostatic agents may prevent bacterial cells from proliferating. The bacteriostatic effect may be reversed upon removal of the antimicrobial polypeptide or the pharmaceutically acceptable salt thereof, allowing bacterial growth to resume. In contrast, "bactericidal activity” refers to the ability to kill bacterial cells, resulting in their irreversible destruction and, thus, a reduction in the number of viable cells compared to the number of viable cells present at the start of the treatment.

[0060] In one embodiment, the polypeptide or the pharmaceutically acceptable salt thereof has heparin- and LPS-binding activity. Methods suitable for determining the binding of a polypeptide to heparin and LPS are known in the art and suitable methods are also provided herein in the Examples section.

[0061] In one embodiment, the polypeptide or the pharmaceutically acceptable salt thereof, as defined in the aspects above, is cyclised. Without wishing to be bound by theory, a cyclised polypeptide may advantageously be characterised by enhanced proteolytic stability. Polypeptides may be cyclised using approaches and methodologies known in the art, for example, as disclosed in Hayes et al., "Approaches for peptide and protein cyclisation”, 2021, Org. Biomol. Chem., vol. 19, issue 18, pp: 3983-4001.

[0062] In particular embodiments, the polypeptide or the pharmaceutically acceptable salt thereof, as defined in the aspects above, comprises the amino acid sequence of SEQ ID NO: 2 or of a variant of SEQ ID NO: 2 comprising up to 5 residue substitutions.

[0063] In more particular embodiments, the polypeptide or the pharmaceutically acceptable salt thereof is from 20 to 22 amino acid residues in length and comprises the amino acid sequence of SEQ ID NO: 2 or of a variant of SEQ ID NO: 2 comprising up to 5 residue substitutions.

[0064] In particular embodiments of the polypeptide or the pharmaceutically acceptable salt as defined above, the variant comprises up to 4, up to 3, or up to 2 residue substitutions compared to the amino acid sequence of SEQ ID NO: 2. In a more particular embodiment, the variant comprises 3, particularly 2, more particularly 1,residue substitutions compared to the amino acid sequence of SEQ ID NO: 2. In more particular embodiments, the residue substitutions are conservative residue substitutions.

[0065] Experimental data disclosed herein in the Examples demonstrate the importance of certain amino acid residues in mediating heparin- and LPS-binding of the polypeptides. Specifically, the experimental data implicate amino acids in positions 1, 3, 8, 9, 10, 12, 13 and 14 of SEQ ID NON (corresponding to the same positions in SEQ ID NO: 2), more particularly amino acids in positions 9, 10 and 14 of SEQ ID NON (corresponding to the same positions in SEQ ID NO: 2). Without wishing to be bound by theory, amino acids in positions 9, 10 and 14 of SEQ ID NO: 1 or SEQ ID NO: 2 (the two sequences are identical from position 1 to position 20) belong to a CPC' motif and play key roles in mediating the polypeptides' biological functions, such as binding to heparin and LPS. The "CPC motif' as used herein refers to a specific sequence of amino acids that appears in some heparin-binding proteins and which mediates the interaction of said proteins with heparin or other sulphated glycosaminoglycans, as disclosed in Torrent et al., "The "CPC clip motif": a conserved structural signature for heparin-binding proteins”, 2012, PLoS One, vol. 7, issue 8, e:42692, and in Pulido et al., "Structural similarities in the CPC clip motif explain peptide-binding promiscuity between glycosaminoglycans and lipopolysaccharides”, 2017, J R Soc Interface, vol. 14, issue 136, e:20170423. In one embodiment, the residue substitutions are not at positions 9, 10 or 14 of SEQ ID NO: 2 (corresponding to the same positions in SEQ ID NO: 1). In an alternative embodiment, residue substitutions comprised in the variant of SEQ ID NO: 2 are residue substitutions at positions selected from positions 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 15, 16, 17, 18, 19, and 20 of SEQ ID NO: 2.

[0066] In one embodiment, the residue substitutions are not at positions 1, 3, 8, 9, 10, 12, 13 or 14 of SEQ ID NO: 2. In an alternative embodiment, residue substitutions comprised in the variant of SEQ ID NO: 2 are residue substitutions at positions selected from positions 2, 4, 5, 6, 7, 11, 15, 16, 17, 18, 19, and 20 of SEQ ID NO: 2. Thus, in particular embodiments of the polypeptide or the pharmaceutically acceptable salt as defined above in aspects of the present disclosure, the variant comprises one or more of: Histidine at position 9, Arginine at position 10, and Arginine at position 14, of SEQ ID NO: 1 or SEQ ID NO: 2.

[0067] In further particular embodiments, the variant comprises one or more of: (I) a residue independently selected from Histidine, Lysine, and Arginine atone or more positions selected from positions: 1, 3, 9, 10, 13 or 14; (ii) a residue selected from Phenylalanine, Tyrosine, and Tryptophan at position 12; and (ill) a residue selected from Serine, Cysteine, Selenocysteine, Threonine, and Methionine at position 8; of SEQ ID NO: 1 or SEQ ID NO: 2.

[0068] In even more particular embodiments, the variant comprises: Histidine at position 9, Arginine at position 10; and Arginine at position 14 of SEQ ID NO: 1 or SEQ ID NO: 2.

[0069] In more particular embodiments, the variant comprises one or more of: Histidine at position 1; Lysine at position 3; Threonine at position 8; Phenylalanine at position 12; and Arginine at position 13. In even more particular embodiments, the variant comprises one or more of: Histidine at position 1; Lysine at position 3;Threonine at position 8; Phenylalanine at position 12; and Arginine at position 13; of SEQ ID NO: 1 or SEQ ID NO: 2.

[0070] In particular embodiments, the polypeptide or the pharmaceutically acceptable salt thereof comprises an amino acid sequence identical to SEQ ID NO: 2. In more particular embodiments, the amino acid sequence of the polypeptide or of the pharmaceutically acceptable salt thereof is identical to SEQ ID NO: 2. In another particular embodiment, the polypeptide or the pharmaceutically acceptable salt thereof consists of the amino acid sequence of SEQ ID NO: 2.

[0071] In further particular embodiments, the polypeptide or the pharmaceutically acceptable salt thereof comprises an N-terminal and / or C-terminal modification.

[0072] In further particular embodiments, the polypeptide or the pharmaceutically acceptable salt thereof comprises one or more D-enantiomers of amino acids. In a more particular embodiment, all the amino acid residues of the polypeptide are D-enantiomers.

[0073] In one embodiment, the polypeptide is an isolated, synthetic, or recombinant polypeptide. "Isolated” means altered or removed from its natural state.

[0074] In a second aspect, the present disclosure also provides a conjugate or a pharmaceutically acceptable salt thereof comprising: the polypeptide or the pharmaceutically acceptable salt thereof as defined above in aspects of the present disclosure, and one or more conjugate moieties. In this sense, a polypeptide "conjugate” refers to a macromolecule in which the polypeptide, or the pharmaceutically acceptable salt thereof, is covalently attached to another molecule and / or to a functional group. Polypeptides may be conjugated with further molecules or functional groups to enhance their properties or to broaden their applications. For example, in the case of antimicrobial polypeptides such as the polypeptides of the present disclosure, conjugation can improve stability, bioavailability, specificity, or broaden the spectrum of antimicrobial activity. The skilled person, using common general knowledge, can select appropriate conjugate moieties for achieving a desired advantageous effect. Conjugates or pharmaceutically acceptable salts thereof comprising the polypeptide of the present disclosure, or comprising the pharmaceutically acceptable salt thereof, may be produced utilising methods known in the art.

[0075] In one embodiment, the one or more conjugate moieties is one or more heterologous conjugate moieties. As used herein, "heterologous conjugate moiety” refers to a moiety that is not found attached to the polypeptide of the disclosure in nature.

[0076] In a particular embodiment, the conjugate is selected from a list consisting of: a polypeptide-drug conjugate, a polypeptide-lipid conjugate, a polypeptide-polymer conjugate, a polypeptide-glycopeptide conjugate, a polypeptide-nanoparticle conjugate, a polypeptide-antibody conjugate, and a polypeptide-peptide conjugate. In a further particular embodiment, the one or more conjugate moieties comprises a polymer, an amino group, an acyl group, an alkyl group, a phosphate group, a lipid or a sugar. In a more particular embodiment, thepolymer is a biological polymer selected from the group consisting of: a polynucleotide, a peptide, a polypeptide, and a polysaccharide. Where the conjugate or the pharmaceutically acceptable salt thereof comprises a peptide, this may be, for example, a signal peptide. In this sense, a "signal peptide” refers to a short amino acid sequence, typically added to either the N- or the C-terminal end of a polypeptide, that serves to direct the polypeptide to specific target sites, such as, but not limited to, specific tissues or cell types, or to specific subcellular locations or to the plasma membrane of prokaryotes. The conjugate or the pharmaceutically acceptable salt thereof may additionally, or alternatively, comprise a peptide linker, optionally wherein the peptide linker comprises an enzyme cleavage site. In this sense, a "peptide linker” refers to a short amino acid chain that connects the polypeptide or the pharmaceutically acceptable salt thereof with at least one of the one or more conjugate moieties. A linker may comprise flexible or neutral amino acids that provide spatial separation between two molecular components of the conjugate or of the pharmaceutically acceptable salt thereof (e.g., between the polypeptide and a conjugate moiety), thus allowing for independent function while maintaining the stability and integrity of the overall conjugate structure. Suitable peptide linkers are known in the art, and the skilled person, using common general knowledge, may select appropriate linkers for use in the context of the present disclosure.

[0077] In an alternative more particular embodiment of the conjugate or the pharmaceutically acceptable salt thereof, the polymer is a synthetic polymer, particularly a peptoid. The skilled person is aware that a “peptoid” refers to a synthetic polymer that mimics peptides, but which comprises monomers with side chains attached to the nitrogen atom of the peptide backbone.

[0078] In an even more particular embodiment, the one or more conjugate moieties comprises a peptide or a polypeptide, wherein the amino acid sequence of the peptide or of the polypeptide comprised in the one or more conjugate moieties has a sequence identity of 50% or lower compared to a flanking sequence, wherein the flanking sequence is comprised in heparin cofactor 2 adjacent to the amino acid sequence of SEQ ID NO:2 and wherein the flanking sequence is of the same length as the peptide or the polypeptide comprised in the one or more conjugate moieties. In this sense, "flanking sequence” refers to amino acid sequences comprised in heparin cofactor 2 that are adjacent to the amino acid sequence of SEQ ID NO:2. In other word, "flanking sequence” refers to amino acid sequences comprised in heparin cofactor 2 that are found immediately downstream or immediately upstream to the amino acid sequence of SEQ ID NO:2. The skilled person understands that, in the context of an amino acid sequence, "upstream” refers to sequences that are comprised before the N-terminus of SEQ ID NO:2, whereas "downstream” refers to sequences that are comprised after the C-terminus of SEQ ID NO:2.

[0079] As identified above, in a third aspect, the present disclosure provides a polynucleotide encoding the polypeptide as defined above in aspects of the present disclosure. The skilled person understands that a "polynucleotide” refers to a polymer composed of nucleotide monomers linked by phosphodiester bonds. Polynucleotides include both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), as well as synthetic or modified nucleic acids. Polynucleotides vary in length from a few nucleotides to thousands or millions of nucleotides. The specific sequence of nucleotides within a polynucleotide determines the genetic informationit encodes.

[0080] Thus, in one embodiment of the third aspect, the polynucleotide is DNA (single or double stranded) or RNA. In another embodiment, the polynucleotide is an isolated, synthetic, or recombinant polynucleotide. In a more particular embodiment, the polynucleotide comprises a sequence optimised for expression in one or more cell types. For example, the polynucleotide sequence may be optimised for expression in a mammalian cell (e.g., a HEK 293T cell). The polynucleotide sequence may be codon optimised for expressing in a mammalian cell using methods known in the art, such as Integrated DNA Technologies (IDT), GeneArt, CoIler, and GenScript. In a further, fourth aspect, the disclosure provides a construct comprising the polynucleotide of the third aspect. A "construct”, also known as a "vector”, refers to a recombinant or engineered nucleic acid molecule that has been artificially assembled, using molecular biology techniques, by combining one or more genetic elements, such as genes, regulatory sequences, promoters, or other functional DNA or RNA sequences. Constructs may be utilised in a range of molecular biology applications for purposes such as gene expression, polypeptide production, genetic modification, or functional analysis. In particular, in the context of the present disclosure, a construct may be used to produce an antimicrobial polypeptide.

[0081] In a particular embodiment, the construct is an expression vector. The skilled person understands that an "expression vector” refers to a construct designed for the introduction and expression of a polynucleotide sequence within a host cell. The expression vector may contain elements such as a promoter to drive gene transcription, an origin of replication for maintaining the vector within the host, selectable markers for identifying successful transformants, and / or a cloning site for inserting the gene of interest. Examples of suitable expression vectors include those conventionally used in biomedicine and known to the skilled person, which includes vectors designed for expression in prokaryotic or eukaryotic cells. For example, vectors can be expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression vectors), yeast cells, or mammalian cells. Alternatively, expression vectors can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

[0082] As defined above, in a fifth aspect, the present disclosure also provides a host cell comprising the polynucleotide according to the third aspect or the construct according to the fourth aspect. As used herein, a "host cell” refers to a cell that has been transfected, transformed, or otherwise introduced with a construct or a polynucleotide. The construct or polynucleotide may be comprised within the host cell's genome, or it may be comprised in the host cell in an extrachromosomal form. The host cell can be of any organism, including bacterial cells, yeast cells, plant cells, or animal cells. In particular, animal cells may be mammalian cells. Further provided herein, in a sixth aspect, is a pharmaceutical composition comprising a pharmaceutically effective amount of the polypeptide or the pharmaceutically acceptable salt thereof, or of the conjugate or the pharmaceutically acceptable salt thereof, as defined above in aspects of the present disclosure, and at least one pharmaceutically acceptable excipient.

[0083] A "pharmaceutical composition” as used herein refers to a formulation that comprises a therapeuticallyeffective amount of either the polypeptide or the pharmaceutically acceptable salt thereof as defined herein, or of the conjugate or the pharmaceutically acceptable salt thereof as defined herein, as an active pharmaceutical ingredient (API), combined with suitable excipients, designed to facilitate the effective delivery and administration of the API for therapeutic purposes. The composition may be formulated for various routes of administration, including oral, topical, intravenous, or other modes of administration, and may include additional components to improve stability, bioavailability, and patient compliance.

[0084] The expression "pharmaceutical composition” encompasses both compositions intended for human as well as for non-human animals.

[0085] The expression "therapeutically effective amount" as used herein, refers to the amount of the polypeptide or the pharmaceutically acceptable salt thereof, or of the conjugate or the pharmaceutically acceptable salt thereof, that, when administered, is sufficient to prevent development of, or to alleviate to some extent, one or more of the symptoms of the disease which is addressed. The particular dose of compound administered according to this disclosure will of course be determined by the particular circumstances surrounding the case, including the compound administered, the route of administration, the particular condition being treated, and the similar considerations.

[0086] The expression "pharmaceutically acceptable excipients" refers to pharmaceutically acceptable materials, compositions or vehicles. Each component must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the pharmaceutical composition. It must also be suitable for use in contact with the tissue or organ of humans and non-human animals without excessive toxicity, irritation, allergic response, immunogenicity or other problems or complications commensurate with a reasonable benefit / risk ratio.

[0087] Examples of suitable pharmaceutically acceptable excipients are solvents, dispersion media, carriers, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like. Except insofar as any conventional excipient medium is incompatible with a substance or its derivatives, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this disclosure.

[0088] The relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and / or any additional ingredients in a pharmaceutical composition of the disclosure will vary, depending upon the identity, size, and / or condition of the subject treated and further depending upon the route by which the composition is to be administered.

[0089] Pharmaceutically acceptable excipients used in the manufacture of pharmaceutical compositions include, but are not limited to, inert diluents, dispersing and / or granulating agents, surface active agents and / or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and / or oils. Excipients such as colouring agents, coating agents, sweetening, and flavouring agents can be present inthe composition, according to the judgment of the formulator.

[0090] The pharmaceutical compositions containing the polypeptide or the pharmaceutically acceptable salt thereof, or the conjugate or the pharmaceutically acceptable salt thereof, of the disclosure can be presented in any dosage form, for example, solid or liquid, and can be administered by any suitable route, for example, oral, parenteral, rectal, topical, intranasal or sublingual route, for which they will include the pharmaceutically acceptable excipients necessary for the formulation of the desired dosage form, for example, topical formulations (ointment, creams, lipogel, hydrogel, etc.), eye drops, aerosol sprays, injectable solutions, osmotic pumps, etc.

[0091] Exemplary diluents include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, and combinations thereof.

[0092] Exemplary granulating and / or dispersing agents include, but are not limited to, potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked polyvinylpyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, and combinations thereof.

[0093] Exemplary binding agents include, but are not limited to, starch (e.g., corn-starch and starch paste); gelatin; sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol); natural and synthetic gums (e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, polyvinylpyrrolidone), magnesium aluminium silicate (Veegum), and larch arabogalactan); alginates; polyethylene oxide; polyethylene glycol; inorganic calcium salts; silicic acid; polymethacrylates; waxes; water; alcohol; and combinations thereof. Exemplary preservatives may include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives. Exemplary antioxidants include, but are not limited to, alpha tocopherol, ascorbic acid, ascorbyl palmitate, ascorbyl stearate, ascorbyl oleate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite. Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, disodium edetate, dipotassium edetate, edetic acid, fumaric acid, malic acid, phosphoric acid, sodium edetate, tartaric acid, and trisodium edetate.Exemplary buffering agents include, but are not limited to, citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, and combinations thereof.

[0094] Exemplary lubricating agents include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and combinations thereof.

[0095] As described above, an eight aspect of the disclosure relates to the polypeptide or the pharmaceutically acceptable salt thereof, the conjugate or the pharmaceutically acceptable salt thereof, the pharmaceutical composition, the polynucleotide, the construct or the host cell, as defined above in aspects of the present disclosure, for use as a medicament.

[0096] In one embodiment of the eighth aspect, the polypeptide or the pharmaceutically acceptable salt thereof, the conjugate or the pharmaceutically acceptable salt thereof, the pharmaceutical composition, the polynucleotide, the construct or the host cell as defined above in aspects of the present disclosure is for use as a medicament in a subject, particularly a mammal, more particularly a human. In more particular embodiments, the human is a female.

[0097] Furthermore, a ninth aspect provides the polypeptide or the pharmaceutically acceptable salt thereof, the conjugate or the pharmaceutically acceptable salt thereof, the pharmaceutical composition, the polynucleotide, the construct, or the host cell, as defined above in aspects of the present disclosure for use in the treatment and / or prevention of a pathological condition caused by a microbe. This aspect can also be formulated as the use of the polypeptide or the pharmaceutically acceptable salt thereof, of the conjugate or the pharmaceutically acceptable salt thereof, of the pharmaceutical composition, of the polynucleotide, of the construct or of the host cell, as defined above in aspects of the present disclosure, for the manufacture of a medicament for the treatment and / or prevention of a pathological condition caused by a microbe.

[0098] Alternatively, the ninth aspect may be formulated as a method of treating and / or preventing a pathological condition caused by a microbe in a subject in need of thereof, the method comprising administering a therapeutically effective amount of the polypeptide or the pharmaceutically acceptable salt thereof, of the conjugate or the pharmaceutically acceptable salt thereof, of the pharmaceutical composition, of the polynucleotide, of the construct, or of the host cell, as defined above in aspects of the present disclosure.Illustrative non-limiting examples of pathological conditions caused by microbes which can be treated with the polypeptide or the pharmaceutically acceptable salt thereof, the conjugate or the pharmaceutically acceptable salt thereof, the pharmaceutical composition, the polynucleotide, the construct or the host cell of the present disclosure include, although they are not limited to, Urinary tract infections (UTIs) caused by Escherichia coll, pneumonia induced by Klebsiella pneumoniae, sepsis resulting from Pseudomonas aeruginosa, meningitis caused by Neisseria meningitidis, chronic wound infections associated with Acinetobacter baumannii, gastroenteritis due to Salmonella enterica, cholera caused by Vibrio cholerae, gastric ulcers and gastric cancer linked to Helicobacter pylori, typhoid fever resulting from Salmonella Typhi, dysentery caused by Shigella spp., endocarditis associated with Haemophilus influenzae, sexually transmitted infections caused by Neisseria gonorrhoeae, periodontitis resulting from Porphyromonas gingivalis, bloodstream infections associated with Enterobacter cloacae, pneumonia in cystic fibrosis and ventilator-associated pneumonia, chronic wound infections in diabetic foot ulcers and burn wounds, bacteremia leading to sepsis, urinary tract infections in catheterized patients, keratitis and endophthalmitis in contact lens users and post-surgical patients, otitis externa (swimmer's ear) and malignant otitis externa in diabetics, meningitis and ventriculitis following neurosurgical procedures, peritonitis in peritoneal dialysis patients, osteomyelitis following trauma or surgery, infective endocarditis in intravenous drug users, soft tissue infections in immunocompromised individuals, chronic sinusitis in individuals with nasal polyps, prosthetic joint infections after orthopedic surgery, catheter-associated bloodstream infections, and necrotizing fasciitis in severe soft tissue infections. In one embodiment of the ninth aspect, the microbe is a bacterium, particularly a Gram-negative bacterium, more particularly a bacterium of the genus Pseudomonas, most particularly a bacterium of the species Pseudomonas aeruginosa.

[0099] In a particular embodiment of the ninth aspect, the pathological condition caused by a microbe is an infection with a Gram-negative bacterium, particularly an infection with a bacterium of the genus Pseudomonas, most particularly an infection with a bacterium of the species Pseudomonas aeruginosa.

[0100] In an alternative particular embodiment of the ninth aspect, the pathological condition caused by a microbe is an infection of an organ selected from a list consisting of: skin, eyes, ear, gums, mouth, stomach, small intestine, large intestine, vagina, lung, kidney, urinary bladder, liver, pancreas, spleen, and combinations thereof.

[0101] In a further particular embodiment of the ninth aspect, the pathological condition caused by a microbe is sepsis.

[0102] In a yet further particular embodiment, the microbe is a multi-drug-resistant microbe, particularly a multi-drug-resistant bacterium, more particularly a multi-drug-resistant Gram-negative bacterium, even more particularly a multi-drug-resistant bacterium of the Pseudomonas genus, most particularly a multi-drug-resistant bacterium of the Pseudomonas aeruginosa species.

[0103] In one embodiment, the treatment and / or prevention of a pathological condition caused by a microbe is thetreatment and / or prevention of a pathological condition caused by a microbe in a subject, particularly a mammal, more particularly a human. In more particular embodiments, the human is a female.

[0104] As explained above, a tenth aspect of the present disclosure provides an in vitro method for disinfecting a material and / or surface, the method comprising contacting the polypeptide or the pharmaceutically acceptable salt, or the conjugate or the pharmaceutically acceptable salt, as defined above in aspects of the present disclosure, with the material and / or surface. Alternatively, the tenth aspect may be formulated as an in vitro use of the polypeptide or the pharmaceutically acceptable salt thereof, or of the conjugate or the pharmaceutically acceptable salt thereof, as defined above in aspects of the present disclosure, for disinfecting materials and / or surfaces.

[0105] In an embodiment, the in vitro method for disinfecting a material and / or surface comprises the step of: (a) contacting a disinfecting composition with the material and / or surface, wherein the disinfecting composition comprises the polypeptide or the pharmaceutically acceptable salt thereof, or the conjugate or the pharmaceutically acceptable salt thereof, as defined above in aspects of the present disclosure; particularly for a period of time sufficient to achieve a reduction in microbial load.

[0106] In a further embodiment, the method comprises an additional step: (b) removing the disinfecting composition from the material and / or surface after the contacting in step (a). The disinfecting composition may be removed, for example, by wiping, rinsing, or air-drying the material and / or surface.

[0107] In a particular embodiment, the disinfecting composition is applied in a concentration effective to reduce the microbial load by at least 99%, particularly by at least 99.9%, after the contact period.

[0108] In another particular embodiment, the contacting in step (a) is performed for a period from 1 minute to 30 minutes. The skilled person, using common general knowledge and through routine testing, is able to select the most appropriate period of time depending on the material and / or surface to be disinfected and the extent of microbial contamination present on said material and / or surface.

[0109] In the context of the present disclosure, the material and / or surface may be particularly selected from the group consisting of countertops, medical devices, food processing equipment, and laboratory instruments. The material and / or surface may be particularly selected from the group consisting of fabric, plastic, glass, metal, and rubber.

[0110] In a further particular embodiment, the material and / or surface is an abiotic material and / or surface.

[0111] In the context of the present disclosure, "microbial load” on a material or surface refers to the total number of viable microorganisms present on or adhering to the material or surface. Microbial load may be determined in relation to surface area, to volume, or to weight, as the number of viable microorganisms per unit of surface area, per unit of volume, or per unit of weight, respectively. The skilled person is familiar with methods for determining microbial load, such as, for example, colony-forming unit (CFU) counting, PCR-based quantifications (including quantitative PCR, qPCR, and droplet digital PCR, ddPCR), ATP bioluminescenceassays and other metabolic activity-based methods, turbidimetric methods, microscopy-based methods, sequencing or electrochemical methods and flow cytometry. Microbial load may be employed as an indicator of the extent of microbial contamination of the material and / or surface, and a reduction in microbial load following exposure to a disinfecting composition may be used to assess the efficacy of disinfection.

[0112] In a particular embodiment, the microbial load is determined by culturing the microorganisms on a growth medium and measuring colony-forming units (CFU).

[0113] In an eleventh aspect, the present disclosure relates to a process for the production of the polypeptide as defined above in aspects of the present disclosure, the process comprising (I) culturing the host cell as defined in the fifth aspect of the present disclosure; or, alternatively, (II) in vitro transcription and / or translation of the polynucleotide as defined in the third aspect of the present disclosure or of the construct as defined in the fourth aspect of the present disclosure.

[0114] In an embodiment, the host cell is a prokaryotic or eukaryotic cell.

[0115] In a further embodiment, the host cell is a mammalian cell, insect cell, yeast cell, or bacterial cell.

[0116] In another embodiment, the process of the eleventh aspect further comprises isolating and / or purifying the polypeptide.

[0117] In a particular embodiment, the in vitro transcription and / or translation is performed using a cell-free system. Methods suitable for in vitro transcription are known in the art, for example, as summarised in Kang etal., "Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics”, 2023, Adv Drug Deliv Rev, vol. 199, e:114961, or in Beckert and Masquida, "Synthesis of RNA by in vitro transcription”, book chapter in: Nielsen, H. (eds), "RNA. Methods in Molecular Biology”, vol 703, Humana Press, Totowa, (USA), pp. 29-41.

[0118] Similarly, methods suitable for in vitro translation are also known in the art, for example, as disclosed in Bothe and Ban, "A highly optimized human in vitro translation system”, 2024, Cell Rep Methods, vol. 4, issue 4, e: 100755, or in Aleksashin etal., "A highly efficient human cell-free translation system”, 2023, RNA, vol. 29, issue 12, pp: 1960-1972.

[0119] The sequences provided in the present application are disclosed in Table 1 below:

[0120] Table 1:

[0121] SEQ ID NO: Polypeptide Amino Acid Sequence

[0122] name

[0123] SEQ ID NO: 1 HBP-5 HNLFRKLTHRLFRRNFGYTLRSV

[0124] SEQ ID NO: 2 HBP-5[1-20] HNLFRKLTHRLFRRNFGYTL

[0125] SEQ ID NO: 3 R10 HNLFRKLTHQLFRRNFGYTLRSV

[0126]

[0127] SEQ ID NO: 4 R14 HNLFRKLTHRLFRQNFGYTLRSVSEC ID NO: 5 ACPC HNLFRKLTAALFRANFGYTLRSV

[0128] SEC ID NO: 6 LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES

[0129]

[0130] SEC ID NO: 7 NLF20 NLFRKLTHRLFRRNFGYTLR

[0131] Throughout the description and claims the word "comprise" and variations of the word, are not intended to exclude other technical features, additives, components, or steps. Furthermore, the word "comprise” encompasses the case of "consisting of”. Additional objects, advantages and features of the disclosure will become apparent to those skilled in the art upon examination of the description or may be learned by practice of the disclosure. The following examples and drawings are provided by way of illustration, and they are not intended to be limiting of the present disclosure. Furthermore, the present disclosure covers all possible combinations of particular and preferred embodiments described herein.

[0132] For the sake of completeness, the invention is additionally laid down in the following numbered clauses: Clause 1. A polypeptide or a pharmaceutically acceptable salt thereof consisting of from 19 to 22 consecutive amino acid residues of SEQ ID NO: 1 or of a variant of SEQ ID NO: 1 comprising up to 5 residue substitutions.

[0133] Clause 2. The polypeptide or the pharmaceutically acceptable salt thereof according to clause 1, wherein the residue substitutions are conservative residue substitutions.

[0134] Clause 3. The polypeptide or the pharmaceutically acceptable salt thereof according to clauses 1 or 2, wherein the polypeptide has antimicrobial activity.

[0135] Clause 4. The polypeptide or the pharmaceutically acceptable salt thereof according to clause 3, wherein the antimicrobial activity is antibacterial activity; particularly wherein the antibacterial activity is against a bacterium of the species Pseudomonas.

[0136] Clause 5. The polypeptide or the pharmaceutically acceptable salt thereof according to clauses 3 or 4, wherein the antimicrobial activity is at least 20% higher compared to the antimicrobial activity of a polypeptide consisting of the amino acid sequence of SEC ID NO: 1, or, wherein the antimicrobial activity comprises a minimum inhibitory concentration (MIC) value that is at least 20% lower than the MIC value of a polypeptide consisting of the amino acid sequence of SEC ID NO: 1.

[0137] Clause 6. The polypeptide or the pharmaceutically acceptable salt thereof according to any one of clauses 1-5, wherein the polypeptide is from 20 to 22 amino acid residues in length and comprises the amino acid sequence of SEC ID NO: 2 or of a variant of SEC ID NO: 2 comprising up to 5 residue substitutions.

[0138] Clause 7. The polypeptide or the pharmaceutically acceptable salt thereof according to clause 6, wherein the variant of SEC ID NO: 2 comprises residue substitutions at positions selected from positions 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 15, 16, 17, 18, 19, and 20 of SEC ID NO: 2.Clause 8. The polypeptide or the pharmaceutically acceptable salt thereof according to clause 6, wherein the variant of SEQ ID NO: 2 comprises residue substitutions at positions selected from positions 2, 4, 5, 6, 7, 11, 15, 16, 17, 18, 19, and 20 of SEQ ID NO: 2.

[0139] Clause 9. The polypeptide or the pharmaceutically acceptable salt thereof according to clause 6, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

[0140] Clause 10. The polypeptide or the pharmaceutically acceptable salt thereof according to clause 9, wherein the polypeptide consists of an amino acid sequence identical to the amino acid sequence of SEQ ID NO: 2. Clause 11. The polypeptide or the pharmaceutically acceptable salt thereof according to any one of clauses 1- 10, wherein the polypeptide comprises an N-terminal and / or C-terminal modification.

[0141] Clause 12. A conjugate or a pharmaceutically acceptable salt thereof, the conjugate or the pharmaceutically acceptable salt thereof comprising: the polypeptide or the pharmaceutically acceptable salt thereof according to any one of clauses 1-11, and one or more conjugate moieties; particularly wherein the one or more conjugate moieties comprises a polymer, an amino group, an acyl group, an alkyl group, a phosphate group, a lipid, a sugar, or combinations thereof.

[0142] Clause 13. A pharmaceutical composition comprising a pharmaceutically effective amount of the polypeptide or of the pharmaceutically acceptable salt thereof according to any one of clauses 1-11, or of the conjugate or of the pharmaceutically acceptable salt thereof according to clause 12, and at least one pharmaceutically acceptable excipient.

[0143] Clause 14. The polypeptide or the pharmaceutically acceptable salt thereof according to any one of clauses 1 to 11, the conjugate or the pharmaceutically acceptable salt thereof according to clause 12, or the pharmaceutical composition according to clause 13, for use as a medicament.

[0144] Clause 15. The polypeptide or the pharmaceutically acceptable salt thereof according to any one of clauses 1- 11, the conjugate or the pharmaceutically acceptable salt thereof according to clause 12, or the pharmaceutical composition according to clause 13, for use in the treatment or prevention of a pathological condition caused by a microbe; particularly for use in the treatment or prevention of an infection with a Gramnegative bacterium.

[0145] Examples

[0146] Materials and Methods:

[0147] Materials

[0148] Escherichia coli BW25113 was obtained from the E. Coli Genetic Stock Center. Acinetobacter baumannii (ATCC 15308), Pseudomonas sp. (ATCC 15915), Staphylococcus aureus (ATCC 12600), Enterococcus faecium (ATCC 19434), Listeria monocytogenes (ATCC 19112), and Streptococcus pyogenes (ATCC 8668) were obtained from CECT (Valencia, Spain). Clinical strains were obtained from the Vail d'Hebron HospitalMicrobiology Service (Barcelona, Spain). MRC-5 and HepG2 cell lines were purchased from ATCC. Bal b / c mice (9-12 weeks old, 20-30 g body weight, male and female) were obtained from Charles River Laboratories. All procedures were approved by the Animal and Human Experimentation Ethics Committee of the Universitat Autbnoma de Barcelona (UAB, Barcelona, Spain). Upon arrival, the animals were acclimated for at least 5 days before the start of the experiment, with free diet and water. Porcine mucin was purchased from Sigma (St. Louis, MO, USA). Horse defibrinated red blood, DISC3(5) (3,3'-dipropylthiadicarbocyanine Iodide), BODIPY® TR cadaverine, and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) were from Thermo Fisher (Hampshire, England). E. co / / lipopolysaccharide (LPS) and heparin were acquired from Merck (Darmstadt, Germany). Heparin disaccharide l-S trisodium salt (H1S) was from TLC Pharmaceutical Standards (Newmarket, ONT) and fondaparinux (Arixtra®) was a gift from the Hospital del Mar (Barcelona, Spain) pharmacy. The deuterated compounds [D38]-DPC (98%), and D2O (99.9%) were purchased from Eurisotop (Saint-Aubin, France). The percentages of deuteration are indicated in parentheses.

[0149] Polypeptides

[0150] Polypeptides were synthesised on H-Rink Amide-ChemMatrix resin in a Prelude instrument (Gyros Protein Technologies, Tucson, AZ) running Fmoc solid-phase peptide synthesis (SPPS) protocols, using methodology as described in Falcao et al., "Structural Dissection of Crotalicidin, a Rattlesnake Venom Cathelicidin, Retrieves a Fragment with Antimicrobial and Antitumor Activity”, 2015, J. Med. Chem., vol. 58, issue 21, pp.

[0151] 8553-8563. After sequence assembly, polypeptides were deprotected and cleaved in TFA / H2O / triisopropylsilane (95:2.5:2.5 v / v), isolated by cold diethyl ether precipitation and centrifugation at 4800 rpm for 5 min, and lyophilised. Purification was performed on a Luna C18 column (21.2 mm x 250 mm, 10 pm; Phenomenex) in a LC-8 preparative RP-HPLC instrument (Shimadzu, Kyoto, Japan) using a linear gradient of solvent B (0.1% TFA in ACN) into A (0.1% TFA in H2O) for 30 min at 25 mL / min flowrate. Prior and after purification, peptides were inspected by analytical RP-HPLC and LC-MS. RP-HPLC was performed on a Luna C18 column (4.6 mm x 50 mm, 3 pm; Phenomenex) in an LC-20AD instrument (Shimadzu) using a linear gradient of solvent B (0.036%TFA in ACN) into A (0.045% TFA in H2O) over 15 min at 1 mL / min flowrate. LC-MS was done in an LC-MS 2010EV instrument (Shimadzu) connected to an Aeris Widepore XB-C18 column (4.6 mm x 150 mm, 3.6 pm; Phenomenex) with a liner gradient of solvent B (0.08% formic acid (FA) in ACN) into solvent A (0.1% FA in H2O) over 15 min at 1 mL / min flowrate. Polypeptides with the expected mass and >95% HPLC homogeneity were lyophilized and stored at -20 °C. RP-HPLC chromatograms and ESI-MS spectra of peptides are included in FIG 1.

[0152] Heparin-binding affinity assay

[0153] Heparin binding was evaluated by affinity chromatography on a Heparin HP column (Cytiva, Marlborough, MA) linked to an AKTA GO FPLC instrument (Cytiva, Marlborough, MA). 10 mL of peptide stocks at 10 pM were loaded in the column, previously equilibrated with binding buffer (10 mM sodium phosphate). Peptides were eluted by a linear gradient of elution buffer (10 mM sodium phosphate, 2 M NaCI) into binding buffer. Heparin affinity for each peptide was defined as the percentage of elution buffer at maximum peak intensity.Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC)

[0154] Antimicrobial activities were determined by the classical microtiter broth dilution method recommended by the National Committee of Laboratory Safety and Standards (NCLSS), adapted for AMPs, as disclosed in Wiegand et al., "Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances”, 2008, Nature Protocols, vol. 3, issue 2, pp. 163-175. Briefly, overnight bacterial cell cultures were brought to an exponential growth state (ODeoo=0.4) in Mueller Hinton (MH) broth and diluted to a final concentration of 5 x 105CFU / mL. 1:2 peptide serial dilutions were prepared in 96-well polypropylene plates (Greiner, Frickenhausen, Germany), in MH broth containing 0.2% (w / v) of bovine serum albumin (BSA) and 0.02% glacial acetic acid. Samples were incubated overnight at 37°C, and 230 rpm, and the MIC was determined as the lowest polypeptide concentration without appreciable visual growth. MBC was determined by transferring the content of the wells to Petri plates with Luria Bertani (LB) agar and incubated overnight at 37 °C. The lowest polypeptide concentration with no colonies was considered the MBC.

[0155] Haemolytic activity

[0156] Polypeptide toxicity was tested on horse erythrocytes, using methodology similar to that described in Sandin et al., "Rationally Modified Antimicrobial Peptides from the N-Terminal Domain of Human RNase 3 Show Exceptional Serum Stability”, 2021, Journal of Medicinal Chemistry, vol. 64, issue 15, pp. 11472-11482. Horse defibrinated blood was washed three times in phosphate buffer saline (PBS) pH 7.2 by centrifugation at 3000 rpm for 10 minutes, to remove excess hemoglobin in the supernatant and then diluted 10-fold in PBS. Next, 50 piL of erythrocytes were added to a 1.5 mL polypropylene tube and incubated with 50 piL of a 1 :2 polypeptide serial dilution prepared in PBS. An erythrocyte disruption (ED) control was prepared by adding 50 piL of 0.1% TritonX-100 in PBS instead of the peptides and an intact erythrocyte (IC) control by adding 50 piL of PBS alone. All samples and controls were incubated for 2 h at 37 °C. Afterwards, samples were centrifuged at 3000 rpm for 3 min and the supernatants were transferred to a polystyrene 96-well plate and inspected for ED by reading the absorbance at 540 nm in a TECAN Spark instrument (Tecan, Mannedorf Switzerland). The hemolysis percentage was calculated as:

[0157] Sample - IC

[0158] Hemolysis (%) = x 100

[0159] tu ■ IU

[0160] Lipopolysaccharide binding affinity

[0161] Displacement of fluorescent cadaverine bound to LPS was used to test peptide affinity to LPS, using methodology similar to that previously disclosed in Torrent et al., "Refining the Eosinophil Cationic Protein Antibacterial Pharmacophore by Rational Structure Minimization”, 2011, Journal of Medicinal Chemistry, vol.

[0162] 54, issue 14, pp. 5237-5244. Briefly, 50 piL of 1:2 polypeptide serial dilutions in 10 mM HEPES were prepared in polystyrene 96-well plates. Then, a previously incubated mixture of 25 piL of 40 pig / mL LPS and 25 piL of 40 pi M cadaverine was added to each well. A control without polypeptides (NP) was prepared by the addition of 50 piL of HEPES buffer, and one without LPS (NL) by adding 25 piL of HEPES instead of LPS. Plates were readfor fluorescence in a TECAN Spark instrument (Tecan, Mannedorf Switzerland), with 580 nm excitation and 620 nm emission wavelengths, and with 5 and 10 nm slits respectively. The fraction of peptide bound to LPS was calculated as:

[0163] Sample - NP

[0164] Binding = — — — -T—

[0165] aNL - NP

[0166] Cytotoxicity in mammalian cells

[0167] Toxicity in MRC-5 and HepG2 cells was tested by the MTT assay, as described in Bello-Madruga et al., "The C-Terminus of Panusin, a Lobster p-Defensin, Is Crucial for Optimal Antimicrobial Activity and Serum Stability”, 2023, Pharmaceutics, vol. 15, issue 6, e:1777. Cell lines were maintained in Eagle's minimum essential medium (MEMo) supplemented with 10% foetal bovine serum (FBS). Cells were cultured in 75 cm2flasks and then transferred to polystyrene 96-well plates, at 3 x 104cells per well, and incubated overnight for attachment to the well surface. Then culture media was removed and 1 :2 peptide serial dilutions in MEMo were added to each well and later incubated for 4 h. After incubation, peptides were removed and 100 piL of 0.5 mg / mL MTT staining solution in MEMo supplemented with 10% FBS was added to cells and incubated for 1.5 h at 37 °C.

[0168] Formazan crystals in living cells were detected after disruption with 200 piL dimethyl sulfoxide and then absorbance was measured at 570 nm in a Tecan Spark instrument (Tecan, Mannedorf Switzerland) following manufacturer's instructions. The results are the average of three independent studies.

[0169] Circular dichroism

[0170] CD spectra of peptides were obtained in different conditions: 5 mM PB, 5 mM PB with 20 pg / mL heparin, and PB 5 mM PBS with 50 pg / mL LPS micelles. Peptides were dissolved in each condition to a final 10 pM concentration. Samples were transferred to a 0.1 mm quartz cuvette (Hellma, Jena, Germany) and then analysed in a Jasco J-815 CD spectropolarimeter (Jasco, Tokyo, Japan) in the 190 to 260 nm range. For each sample, 15 spectra were acquired and averaged. Data were processed with the OriginPro 2018 analysis software and subsequently analysed to predict secondary structure with the CDSSTR method available in the DichroWeb online server (http: / / dichroweb.cryst.bbk.ac.uk / html / home.shtml), according to a method as disclosed in Miles et al., "DichroWeb, a website for calculating protein secondary structure from circular dichroism spectroscopic data”, 2022, Protein Science, vol. 31, issue 1, pp. 37-46. The molar mean ellipticity [0] was calculated using:

[0171] 0 (mdeg) x MRW

[0172] [0]MRW(deg xcm2x dmof1) =

[0173] L (mm) x c (mg / mL)

[0174] where [0]MRW is the mean molar ellipticity by residue, MRW is the molecular weight of peptides divided by the number of residues minus one, 0 is the ellipticity, L is the optical path (1.0 mm) and, c is the concentration.

[0175] NMR spectroscopyNMR samples were prepared by dissolving lyophilized peptide HBP-5 at about 1 mM concentration in aqueous solution (H2O / D2O 9:1 v / v), or in aqueous solution with the heparin analog Arixtra or the heparin disaccharide H1S (molar ratios 1:1, 1:0.5). pH was measured using a glass micro-electrode and adjusted to 4.4 by addition of NaOD or DCI. Sodium 2,2-dimethyl-2-silapentane-5-sulfonate (DSS) at a 0.1-0.2 mM concentration was added as internal reference for the1H chemical shifts. A Bruker AVNEO600 spectrometer (Bruker Biospin, Karlsruhe, Germany) equipped with a cryoprobe was used to record NMR spectra: 1D1H, 2D1H,1H-DFQ-COSY (double-filtered-quantum phase-sensitive two-dimensional correlated spectroscopy),1H,1H- TOCSY (total correlated spectroscopy),1H,1H-NOESY (nuclear Overhauser enhancement spectroscopy), and1H-13C-HSQC (heteronuclear single quantum coherence) at13C natural abundance. TOCSY and NOESY mixing times were 60 ms and 150 ms, respectively. Data were processed using the TOPSPIN software (Bruker Biospin, Karlsruhe, Germany). The NMRFAM-SPARKY software (described in Lee et al., "NMRFAM- SPARKY: enhanced software for biomolecular NMR spectroscopy”, 2014, Bioinformatics, 2014, vol. 31, issue 8, pp. 1325-1327), was used to analyse the NMR spectra.1H chemical shifts were assigned by analysis of the 2D homonuclear spectra using the well-established sequential assignment methodology (as previously disclosed in Wishart etal., “1 H, 13C and 15N random coil NMR chemical shifts of the common amino acids. I. Investigations of nearest-neighbor effects”, 1995, J. Biomol. NMR, vol. 5, issue 1, pp. 67-81), and1H-13C- HSQC spectra were analysed to assign the13C chemical shifts. The assigned chemical shifts have been deposited at the BioMagResBank (http: / / www.bmrb.wisc.edu) with accession codes BMRB ID: 51732 (HBP-5 in aqueous solution) and 51740 (HBP-5 / H1S 1:1). The conformational shifts (A5HQand A5ca) were obtained as the differences between the observed chemical shifts and those in random coil (RC) peptides: A5HQ=

[0176]

[0177] 5Haobserved > g^RC ppm an(j = ^observed > g^RC ppmg^RCan(j g^RCweretaken fromWishart et al., "1 H, 13C and 15N random coil NMR chemical shifts of the common amino acids. I. Investigations of nearest- neighbor effects”, 1995, J. Biomol. NMR, vol. 5, issue 1, pp. 67-81. A weighted value for the chemical shift changes (A5w, ppm) was defined as:

[0178] A6w = I(5HNBOUND- 6HNfree)2 +(5Habound- 5Hafree)2]1 / 2

[0179] Considering all HBP-5 residues (23 in total), the mean A5Wis 0.05 ppm. Residues with A5W> 0.05 ppm can be considered as those most affected by interaction.

[0180] Molecular dynamics simulations

[0181] MD simulations with or without Arixtra were conducted using GROMACS v2022.3. The Glycan Reader & Modeler from CHARMM-GUI was used to prepare the system, obtaining the topology and parameter files. The force field CHARMM36 was employed for the protein and Arixtra parameters. Initial structures were solvated in a rectangular box of TIP3P water with a minimum distance of 1.0 nm between protein and the faces of the box. K+and Cl- ions were added to neutralize the system at an ionic strength of 0.15 M. Electrostatic interactions were calculated using the particle mesh Ewald method under periodic boundary conditions. Structures were energy-minimized and equilibrated by molecular dynamics for 130 ps. Production simulations were run on a GPU (NVIDIA GeForce RTX 3080 Ti) and 16 CPUs (Intel® Xeon® Gold 6226R CPU @2.90GHz) for 500 ns with a time step of 2 fs. NPT conditions were stabilized at 306 K by a V-rescale thermostat (as disclosed in Buss! et al., "Canonical sampling through velocity rescaling”, 2007, J. Chem. Phys., vol. 126, issue 1, pp. 014101), and at 1 atm by a Parinello-Rahman barostat (as disclosed in Parrinello and Rahman, "Polymorphic transitions in single crystals: A new molecular dynamics method”, 1981, Journal of Applied Physics, vol. 52, pp. 7182-7190). Bonds were constrained using the LINCS algorithm. Representative structures for different analyses were extracted from trajectories with the GROMACS command "gmx cluster”, using the gromos algorithm with a RMSD cutoff of 0.18 nm.

[0182] Serum stability

[0183] Briefly, 500 piL of the peptide stock solution (1mM in MiliQ water) were mixed with 500 piL of human serum (Sigma-Aldrich, St. Louis, MO, USA). The mixture was incubated at 37°C with shaking and at various time points aliquots were taken and proteolysis was stopped with cold acetonitrile (80% in filtered H2O). The samples were chilled at 4°C for 10 min to precipitate serum proteins, and centrifuged at 13,000 rpm at 4°C for 15 min. The supernatant was collected and analysed by LC and LC-MS with a 0-95% linear gradient of acetonitrile over 15 min. The unaltered peptide was determined by RP-HPLC peak integration, expressed as the percent of the amount at 0 min, and data were fitted to a one-phase exponential decay model using GraphPad Prism 8.01 to estimate half-life time (t1 / 2). The results are the average of three independent experiments.

[0184] Mouse systemic infection

[0185] To determine the maximum lethal dose and appropriate doses for the main study, a toxicity study was first conducted. Polypeptides HBP-5 and HBP-5[1 -20] were administered intraperitoneally (i.p.) at initial doses of 30 mg / kg. If toxicity signs or death occurred, a lower dose was administered to another animal. Once the adequate concentration had been determined (HBP-5 and HBP-5[1-20] at 20 mg / kg), three randomly distributed groups of three female mice were administered. Each animal was treated three times a day for three consecutive days to ascertain that the selected doses did not induce toxicity or result in very low or reversible toxicity.

[0186] A systemic infection model was established in mice, following protocols as previously described in the prior art, for example, as disclosed in Li etal., "In Vivo Evaluation of ECP Peptide Analogues for the Treatment of Acinetobacter baumannii Infection”, Biomedicines, 2022, vol. 10, issue 2, pp. 386. Briefly, an aliquot of Acinetobacter baumannii (ATCC 15308) stock stored at -80°C in 15% glycerol was cultured overnight in 5 mL of MHB at 37°C with shaking at 250 rpm. The overnight bacterial culture was then adjusted to an exponential growth phase (ODeoo = 0.3-0.6) and washed twice with sterile HBS 1X (pH 7.4) by centrifugation at 6000 rpm for 5 minutes. The cells were diluted with an identical volume of 10% porcine mucin solution to achieve a final concentration of 1 x 1 o8CFU / mL. Mucin enhances the infectivity of A. baumannii and acts as an immune system suppressor as disclosed in the prior art. A total of 30 mice (15 male and 15 female), randomly distributed into five groups, were each inoculated (i.p.) with a 10 mL / kg dose. Then, each group was treated intraperitoneally with HBP-5 or HBP-5[1 -20] at 20 mg / kg, LL-37 at 5 mg / kg as positive control, or vehicle HBS1X as negative control. Treatment (performed blindly) was applied 2 h after infection and was administered as three doses applied blindly every six hours. On day 2, animals were euthanised with a 200 mg / kg (i.p.) dose of pentobarbital. For end-of-treatment CFU evaluation, organs of interest (liver, spleen, lung, and kidney) were extracted, weighed, and homogenized in 1 mL HBS. Subsequently, six serial 10-fold dilutions were prepared, and each dilution was seeded (in triplicate) on Petri plates with LB-agar. The colonies were counted after 16 h incubation at 37°C. Final CFU counts are expressed relative to each organ weight in CFU / mg.

[0187] Results:

[0188] Characterisation of residues implicated in the binding to heparin

[0189] To identify residues that mediate interaction with heparin, HBP-5 complexed with H1S disaccharide, a heparin analog, was studied by nuclear magnetic resonance (NMR) spectroscopy and weighted chemical shift differences (A6W, ppm) were plotted as a function of peptide sequence (FIG. 2A). It is clear in this plot that significant differences are mainly located at the central section, residues 8-14 (FIG. 2A). In view of this, and to obtain additional insights into heparin binding of HBP-5 (SEC ID NO: 1), the inventors performed a molecular dynamics simulation with fondaparinux. The results show that the pentasaccharide remains in contact with the peptide all along the simulation time, suggesting strong binding. Specifically, a persistent salt bridge between the Arg13 side chain and the S6 sulfate group of the pentasaccharide was observed (FIG. 2B). Another salt bridge between Arg10 and the S6 sulfate, plus a loosely defined hydrogen bond between His9 and the S3 were also identified. These three residues (His9, Arg10, and Arg14) form a CPC motif with their relative distances maintained throughout the simulation (FIG. 2C), altogether suggesting a CPC clip as a relevant binding element.

[0190] Relevance of residues of the CPC motif to mediating binding to heparin and LPS

[0191] To assess the significance of the CPC motif in mediating binding to heparin, as well as binding to LPS as an indicator of Gram-negative antibacterial activity, two polypeptides, R10 (SEC ID NO: 3) and R14 (SEC ID NO: 4), with the cationic residues within the CPC clip replaced by glutamine were made, plus, polypeptide ACPC' (SEC ID NO: 5), in which the three residues defining the CPC domain - namely residues 9, 10 and 14 of HBP-5 (SEC ID NO: 1) - were replaced by alanine. Table 2, a notable 2-4-fold decrease in antibacterial activity against Gram-negative bacteria was observed for the ACPC polypeptide. These results suggest that recognition of LPS through the CPC motif plays a critical role in the selective activity against Gram-negative bacteria. The LPS-binding assay further illustrated distinctions between CPC-defective peptides and HBP-5. Thus, the EC50 for either R10 or R14 was 2-4-fold higher than that of HBP-5, and for ACPC the increase was 7-fold. Additionally, the CPC-defective peptides showed a substantial reduction in heparin binding, as shown by shorter retention times relative to HBP-5 (Table 2 and FIG. 3). Notably, for ACPC a ca. 20% reduction in elution buffer was required to dislodge the peptide from the column (Table 2 and FIG. 3). Finally, the secondary structure of the peptide variants by CD in both LPS and heparin environments were analysed (FIG.

[0192] 3). Although they retained a helical structure similar to HBP-5, all peptides exhibited a decrease in the molar ellipticity intensity of their respective maxima and minima, consistent with the LPS and heparin-binding results.Taken together, these findings underscore the essential role of the CPC motif in heparin and LPS binding, and, thus, the importance of these residues for the polypeptide's antibacterial activity.

[0193] Table 2: MIC and binding affinity of mutant polypeptides

[0194] Mutant HBP-5 Polypeptides

[0195] HBP-5 R10 R14 ACPC’ E coli 0.4 0.4 0.4 1.6 A. baumannii 0.2 0.4 0.4 1.6

[0196] x Pseudomonas sp 0.8 0.8 0.4 1.6

[0197] |= S. aureus 6.3 6.3 6.3 6.3

[0198] E. faecium 25 12.5 12.5 25

[0199] L. monocytogenes 1.6 1.6 3.1 3.1

[0200] > LPS (EC5o, pM) 0.9 ± 0.7 3.9 ± 1.1 2.3 ± 1.0 6.7 ± 0.8 3= Heparin (% Elution buffer) 98.0 88.6 89.7 80.9

[0201]

[0202] Evaluation of the half-life

[0203]

[0204] inity to LPS and

[0205]

[0206] and in vitro antibacterial

[0207] HBP-5 peptide (SEQ ID NO: 1) was incubated in human serum, and its degradation was monitored over time to determine its half-life. Incubating the HBP-5 in human serum revealed that HBP-5 has a serum half-life of approximately 50 minutes, which is relatively short, potentially limiting its therapeutic efficacy (FIG. 4).

[0208] Interestingly, the inventors found that a shorter variant, which lacks the C-terminal triplet of amino acids Arg-Ser-Val compared to the original HBP-5 polypeptide (SEQ ID NO: 1), and which was denominated HBP-5[1-20] (SEQ ID NO:2), displayed a longer half-life in human serum of approximately 90 minutes - nearly double that of the HBP-5 polypeptide - indicating enhanced stability (FIG. 4A, Table 3). Moreover, the half-life of HBP-5[1-20] in human serum was 8-fold higher than that of a previously known HBP-5-derived polypeptide denominated NLF20 (SEQ ID NO:7) (FIG. 4B, Table 4). Of note, NLF20 is highly similar in sequence and has an identical length to HBP-5[1-20],

[0209] The HPLC profiles and MS spectra of the purified peptides are shown in FIG. 1, while the peptide degradation profiles observed in serum are shown in FIG. 5.

[0210] The antimicrobial activity, cytotoxicity, haemolytic potential, and ability to bind lipopolysaccharide (LPS) and heparin were subsequently characterised for HBP-5[1-20], Compared to the parental HBP-5 peptide, HBP-5[1 -20] exhibited greater antimicrobial activity, while maintaining low cytotoxic and haemolytic effects (Table3). Moreover, HBP-5[1-20] also exhibited greater antimicrobial activity, as evidenced by lower MIC values, compared to the NLF20 peptide (Table 4).

[0211] Table 3: Properties of HBP-5[1-20] polypeptide compared to HBP-5

[0212] Polypeptide

[0213] HBP-5 HBP5 [1-20] MIC (pM) Pseudomonas sp 0.8 0.4

[0214] Toxicity

[0215] Hemolysis (250 pM peptide) 23 ± 1 24 ± 2 EC5o (MRC-5 cells, pM) 69 ± 2 63 ± 1

[0216] ES

[0217] g S Half-life (ti / 2min) 48.9 88.5

[0218] Table 4: Properties of HBP-5[1-20] polypeptide compared to the NLF20 polypeptide

[0219] Polypeptide NLF20 HBP5 [1-20] MIC (pM) E. coli 3.1 0.4

[0220] S. aureus 25 6.3

[0221] Half-life (ti / 2, min) 10.5 88.5 <D RA

[0222] In vivo antimicrobial activity:

[0223] The in vivo antimicrobial efficacy of the HBP-5 parental polypeptide and of the HBP-5[1-20] polypeptide was tested in a murine model of sepsis induced by Acinetobacter baumannii ATCC 15308, as detailed above. In this model, BALB / c mice were intraperitoneally injected with the bacterium, followed by a two-hour incubation to establish infection (FIG. 6A). Subsequently, three doses of each peptide (or vehicle as control) were administered every six hours. After 18 hours, the mice were sacrificed, and colony-forming units (CFUs) in various organs were quantified to assess bacterial load.

[0224] The results revealed a substantial reduction in CFUs across all organs, ranging from 2 to 5 orders of magnitude, depending on the organ and the sex of the animals (FIG. 6B; data plotted on a base 10 logarithmic scale). Notably, the peptides outperformed the positive control polypeptide LL-37 (SEQ ID NO: 6),a known AMP known in the prior art to be efficacious against systemic infection with Acinetobacter baumannii in a similar experimental model, for example, as disclosed in Zarei-Mehrvarz et al., "The LL-37 Antimicrobial Peptide as a Treatment for Systematic Infection of Acinetobacter baumannii in a Mouse Model”, 2023, Protein Pept. Lett., vol. 30, issue 1, pp. 44-53. Interestingly, female mice demonstrated more efficient bacterial clearance than males. In particular, the HBP-5[1-20] peptide showed particularly strong activity in females, achieving reductions of 4 to 8 orders of magnitude in CFUs across all tested organs (FIG. 6B). These findings highlight the improved in vivo antimicrobial activity of the peptides of the disclosure and underscore their potential as therapeutic agents, particularly for use in the treatment of infections caused by Gram-negative bacteria.

[0225] Citation List

[0226] Non-Patent Literature:

[0227] Aleksashin et al., "A highly efficient human cell-free translation system”, 2023, RNA, vol. 29, issue 12, pp: 1960-1972

[0228] Altschul et al., "Basic local alignment search tool”, 1990, J. Mol. Biol, vol. 215, issue 3, pp. 403-410 Andrews, "Determination of minimum inhibitory concentrations”, 2001, J. Antimicrob. Chemother., vol. 48, suppl. issue 1, pp. 5-16.

[0229] Barnes et al., "Antimicrobial susceptibility testing to evaluate minimum inhibitory concentration values of clinically relevant antibiotics”, 2023, STAR Protocols, vol. 4, issue 3, pp. 102512

[0230] Beckert and Masquida, "Synthesis of RNA by in vitro transcription”, book chapter in: Nielsen, H. (eds), "RNA. Methods in Molecular Biology”, vol 703, Humana Press, Totowa, (USA), pp. 29-41

[0231] Bello-Madruga et al., "The C-Terminus of Panusin, a Lobster p-Defensin, Is Crucial for Optimal Antimicrobial Activity and Serum Stability”, 2023, Pharmaceutics, vol. 15, issue 6, e: 1777

[0232] Bothe and Ban, "A highly optimized human in vitro translation system”, 2024, Cell Rep Methods, vol. 4, issue 4, e: 100755

[0233] Buss! et al., "Canonical sampling through velocity rescaling”, 2007, J. Chem. Phys., vol. 126, issue 1, pp. 014101

[0234] European Committee for Antimicrobial Susceptibility Testing (EUCAST), "Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution”, 2003, Clinical Microbiology and Infection, vol.

[0235] 9, issue 8, pp. ix-xv

[0236] Falcao et al., "Structural Dissection of Crotalicidin, a Rattlesnake Venom Cathelicidin, Retrieves a Fragment with Antimicrobial and Antitumor Activity”, 2015, J. Med. Chem., vol. 58, issue 21, pp. 8553-8563Hayes etal., "Approaches for peptide and protein cyclisation”, 2021, Org. Biomol. Chem., vol. 19, issue 18, pp: 3983-4001

[0237] Kang et al., "Advancements of in vitro transcribed mRNA (I VT mRNA) to enable translation into the clinics”, 2023, Adv Drug Deliv Rev, vol. 199, e:114961

[0238] Lee et al., "NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy”, 2014, Bioinformatics, 2014, vol. 31, issue 8, pp. 1325-1327

[0239] Li et al., "In Vivo Evaluation of ECP Peptide Analogues for the Treatment of Acinetobacter baumannii Infection”, Biomedicines, 2022, vol. 10, issue 2, pp. 386

[0240] Miles et al., "DichroWeb, a website for calculating protein secondary structure from circular dichroism spectroscopic data”, 2022, Protein Science, vol. 31, issue 1, pp. 37-46

[0241] Needleman and Wunsch, "A general method applicable to the search for similarities in the amino acid sequence of two proteins”, 1970, J. Mol. Biol., vol. 48, issue 2, pp. 443-453

[0242] Parrinello and Rahman, "Polymorphic transitions in single crystals: A new molecular dynamics method”, 1981, Journal of Applied Physics, vol. 52, pp. 7182-7190

[0243] Pulido et al., "Structural similarities in the CPC clip motif explain peptide-binding promiscuity between glycosaminoglycans and lipopolysaccharides”, 2017, J R Soc Interface, vol. 14, issue 136, e:20170423 Rice et al., "EMBOSS: The European Molecular Biology Open Software Suite”, 2000, Trends Genet, vol. 16, issue 6, pp. 276-277

[0244] Sandin et al., "Rationally Modified Antimicrobial Peptides from the N-Terminal Domain of Human RNase 3 Show Exceptional Serum Stability”, 2021, Journal of Medicinal Chemistry, vol. 64, issue 15, pp. 11472-11482 Torrent et al., "Refining the Eosinophil Cationic Protein Antibacterial Pharmacophore by Rational Structure Minimization”, 2011, Journal of Medicinal Chemistry, vol. 54, issue 14, pp. 5237-5244

[0245] Torrent et al., "The "CPC clip motif": a conserved structural signature for heparin-binding proteins”, 2012, PLoS One, vol. 7, issue 8, e:42692

[0246] Wiegand et al., "Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances”, 2008, Nature Protocols, vol. 3, issue 2, pp. 163-175

[0247] Wishart et al., “1 H, 13C and 15N random coil NMR chemical shifts of the common amino acids. I.

[0248] Investigations of nearest-neighbor effects”, 1995, J. Biomol. NMR, vol. 5, issue 1, pp. 67-81

[0249] Zarei-Mehrvarz et al., "The LL-37 Antimicrobial Peptide as a Treatment for Systematic Infection of Acinetobacter baumannii in a Mouse Model”, 2023, Protein Pept. Lett., vol. 30, issue 1, pp. 44-53

Claims

33Claims1. A polypeptide or a pharmaceutically acceptable salt thereof consisting of from 20 to 22 amino acid residues in length, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2 or of a variant of SEQ ID NO: 2 comprising up to 5 residue substitutions, and wherein the polypeptide has antimicrobial activity.

2. The polypeptide or the pharmaceutically acceptable salt thereof according to claim 1, wherein the residue substitutions are conservative residue substitutions.

3. The polypeptide or the pharmaceutically acceptable salt thereof according to claims 1 or 2, wherein the antimicrobial activity is antibacterial activity.

4. The polypeptide or the pharmaceutically acceptable salt thereof according to claim 3, wherein the antibacterial activity is against a bacterium of the species Pseudomonas.

5. The polypeptide or the pharmaceutically acceptable salt thereof according to claims 3 or 4, wherein the antimicrobial activity is at least 20% higher compared to the antimicrobial activity of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1, or, wherein the antimicrobial activity comprises a minimum inhibitory concentration (MIC) value that is at least 20% lower than the MIC value of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1.

6. The polypeptide or the pharmaceutically acceptable salt thereof according to claims 1-5, wherein the residue substitutions are at positions selected from positions 1 , 2, 3, 4, 5, 6, 7, 8, 11 , 12, 13, 15, 16, 17, 18, 19, and 20 of SEQ ID NO: 2.

7. The polypeptide or the pharmaceutically acceptable salt thereof according to claim 6, wherein the residue substitutions are at positions selected from positions 2, 4, 5, 6, 7, 11, 15, 16, 17, 18, 19, and 20 of SEQ ID NO: 2.

8. The polypeptide or the pharmaceutically acceptable salt thereof according to claims 1-7, wherein the variant comprises: Histidine at position 9, Arginine at position 10; and Arginine at position 14 of SEQ ID NO: 2.

9. The polypeptide or the pharmaceutically acceptable salt thereof according to claim 1-5, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

10. The polypeptide or the pharmaceutically acceptable salt thereof according to claim 8, wherein the polypeptide consists of an amino acid sequence identical to the amino acid sequence of SEQ ID NO:

2.

11. The polypeptide or the pharmaceutically acceptable salt thereof according to any one of claims 1-9, wherein the polypeptide comprises an N-terminal and / or C-terminal modification.

12. A conjugate or a pharmaceutically acceptable salt thereof, the conjugate or the pharmaceutically acceptable salt thereof comprising: the polypeptide or the pharmaceutically acceptable salt thereof according to any one of claims 1-11, and one or more conjugate moieties; particularly wherein the one or moreconjugate moieties comprises a polymer, an amino group, an acyl group, an alkyl group, a phosphate group, a lipid, a sugar, or combinations thereof.

13. A pharmaceutical composition comprising a pharmaceutically effective amount of the polypeptide or of the pharmaceutically acceptable salt thereof according to any one of claims 1-11, or of the conjugate or of the pharmaceutically acceptable salt thereof according to claim 12, and at least one pharmaceutically acceptable excipient.

14. The polypeptide or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 11, the conjugate or the pharmaceutically acceptable salt thereof according to claim 12, or the pharmaceutical composition according to claim 13, for use as a medicament.

15. The polypeptide or the pharmaceutically acceptable salt thereof according to any one of claims 1-11, the conjugate or the pharmaceutically acceptable salt thereof according to claim 12, or the pharmaceutical composition according to claim 13, for use in the treatment or prevention of a pathological condition caused by a microbe; particularly for use in the treatment or prevention of an infection with a Gram-negative bacterium.